Spots Global Cancer Trial Database for Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer

Official Title: Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer

Study ID: NCT01546363

Conditions

Cervical Cancer

Interventions

Blood draw

Study Description

Brief Summary: The purpose of this study is to measure the levels of serum proteins and other biomarkers in cervical cancer patients. We believe that some of these markers may be useful in selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Detailed Description: SPECIFIC STUDY AIMS Specific Aim 1: To use gene expression analysis of primary cervical cancers to identify a gene expression signature that predicts for lymph node metastases in this disease. Specific Aim 2: To predict lymph node metastases by performing multiplex measurements of cancer-associated proteins and cytokines using proximity ligation assay (PLA) on plasma samples. Specific Aim 3: To measure circulating human papilloma virus (HPV) DNA in the plasma samples of cervical cancer patients using real-time quantitative polymerase chain reaction (qPCR) and determine its ability to predict for nodal metastases. Specific Aim 4: To use deep sequencing to evaluate gene and sequence differences between cervical cancer patients with and without lymph node metastasis.